Stock Selection: DeepSeek's picks for 2026-10-12
DeepSeek picked IREN, CCC, CRM, BIIB, FSLR for a 1-day horizon. Portfolio return vs SPY: -1.00%. Picks that beat SPY: 40%.
| Experiment | Stock Selection |
|---|---|
| Model | DeepSeek |
| Prompt version | stock-selection-v8 |
| Asked | |
| Horizon | 1-day |
| Measured from | 2026-10-12 |
| Measured to | 2026-10-13 |
| Benchmark | SPY |
| Status | Settled |
| Portfolio return vs SPY | -1.00% |
| Picks that beat SPY | 40% |
| Benchmark return | -0.06% |
The picks
| Rank | Symbol | Return | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|
| 1 | IREN | -6.85% | 63% | -6.79% | No |
| 2 | CCC | +1.19% | 61% | +1.25% | Yes |
| 3 | CRM | +3.27% | 58% | +3.33% | Yes |
| 4 | BIIB | -2.22% | 56% | -2.16% | No |
| 5 | FSLR | -0.71% | 53% | -0.65% | No |
The model's market view
US equities are trading roughly flat to modestly higher on Columbus Day: the S&P 500 is near record highs and up only about 0.05% intraday, the Dow is up around 0.3%, and the Nasdaq is slightly lower as AI-infrastructure and memory-chip names stay under pressure. With the Treasury market closed, no scheduled US macro data and only a Cleveland Fed speech on the calendar, there is no bond-market signal to confirm or cap moves, so index direction is likely to be muted and flow-driven on light holiday volume. Earnings season effectively starts Tuesday with JPMorgan, Goldman Sachs, Citigroup and Wells Fargo, and CPI/retail sales land later in the week, so traders are positioning ahead of those events rather than committing hard to the index. In that kind of tape, benchmark SPY tends to grind sideways, which means single-stock catalysts (fresh analyst actions, clinical data, AI/cloud deals and M&A) are the most reliable source of same-session outperformance. The five picks below are all high-conviction, news-rich names with abnormal volume that can decouple from a flat index over one session.
Why each pick
IREN
IREN is the strongest single-name catalyst in the market today: The Information reported over the weekend that the company signed a multi-year AI cloud services deal with Anthropic, validating its GPU/data-center buildout and giving the stock a hard-news driver rather than just an analyst opinion. Shares jumped as much as 8.75% overnight and were still up roughly 4% to about $36.70-$36.95 in morning trading, leading the computing-infrastructure complex. IREN is a high-beta, heavily-shorted AI-infrastructure name with retail and momentum flows that can extend on a clean headline, and the deal is strategically significant because it locks in a marquee AI customer ahead of Anthropic's planned IPO. Risks: the initial pop already faded from its pre-market peak, the stock remains below its 50-day moving average near $41.72, and this is an unconfirmed media report rather than a company press release, so a denial, a 'no comment' or a renewed SemiAnalysis-style data-center concern could reverse the move quickly. It is also a volatile bitcoin-miner-turned-AI name with no earnings cushion, so a flat broad tape could still produce an outsized drawdown. Reference price is an intraday quote taken around the window open (Robinhood, 2026-10-12).
CCC
CCC Intelligent Solutions is a live M&A target: Bloomberg reported that private-equity firm GTCR and activist Elliott Investment Management are in advanced talks to acquire the automotive-insurance software company, with a deal possibly announced as soon as this week. M&A targets in advanced talks tend to hold gains and drift toward the expected deal price, and CCC jumped about 9.5% in extended trading Friday to roughly $7.69, with Monday pre-market quotes around $7.75-$7.94 (a 10-13% advance). The presence of Elliott, a sophisticated activist, plus a strategic review, raises the probability that a transaction gets done and gives the stock a floor that is largely independent of the index. Risks: talks are not final and could still collapse or be repriced, in which case the entire takeover premium would unwind in a single session; CCC is a small-cap software name with AI-disruption concerns in its core auto-insurance end market, and a 'no deal this week' headline would be a sharp negative catalyst. Reference price is an intraday/pre-market quote (Robinhood, 2026-10-12).
CRM
Salesforce received a rare Bank of America double upgrade to Buy from Underperform, with the price target more than doubled from $160 to $285 (about 20-24% above the current price). The bull case is that AI will 'deepen dependence' on enterprise software rather than disintermediate it, directly reversing the AI-overhang thesis that had pushed the stock down about 13% year-to-date and left it oversold. The stock jumped about 4% in pre-market and was trading up roughly 3-4% around $236-$238 in morning trading, breaking a short downtrend and reclaiming its 50-day and 10-week moving averages, which is the kind of technical repair that attracts momentum buyers. Risks: analyst-driven moves are prone to intraday fade, RBC reiterated a Neutral rating the same day, and a flat-to-lower software tape (ServiceNow and Palantir were only mixed) could cap upside; if the broader Nasdaq stays soft, CRM may struggle to hold its gap. Reference price is an intraday quote from morning trading (Investors.com / 247wallst, 2026-10-12).
BIIB
Biogen was upgraded to Overweight from Neutral by JPMorgan, which raised its price target to a Street-high $300 from $210 (about 30% upside from Friday's close), citing an 'increasingly compelling catalyst path' and an improved long-term growth outlook. Biotech is a relatively defensive, low-beta corner of the market that can outperform a flat SPY tape, and BIIB was up about 5% to roughly $237 in morning trading on strong volume, significantly more than the broad market. The stock had already been a 2026 winner (up roughly 28% year-to-date before today), so the upgrade reinforces an existing uptrend rather than creating one from scratch. Risks: single-analyst upgrades frequently fade intraday, the current price is near JPMorgan's new target only after the pop, and Biogen carries pipeline/clinical and Alzheimer's-franchise execution risk; if the broader healthcare complex sells off, BIIB's relative gain could compress. Reference price is an intraday quote from the morning session (cnyes market flash, 2026-10-12).
FSLR
First Solar was upgraded to Buy from Hold by Truist, which raised its price target to $270 from $229, implying roughly 52% upside from Friday's close based on a stronger pricing backdrop into the 2030s and a recent valuation reset. FSLR is one of the most beaten-down large-cap clean-energy names (down about one-third this year), so a credible upgrade can trigger aggressive short-covering and mean-reversion flows, and the stock was up about 2.4-3.9% to roughly $183-$185 in morning trading. Solar and clean-energy names are highly sensitive to rate expectations, and with the 10-year yield recently finding support after strong auctions, that macro backdrop is incrementally more favorable. Risks: this is the weakest catalyst of the five (a single analyst upgrade), solar is politically and policy-sensitive with US manufacturing-incentive risk, and FSLR has a history of giving back upgrade gaps quickly; if the broad market turns risk-off ahead of Tuesday's bank earnings, this high-beta name would likely underperform. Reference price is an intraday quote from the morning session (Finet/Chinese financial media, 2026-10-12).
Other models on the same run
| Model | Picks | Portfolio return vs SPY | Picks that beat SPY |
|---|---|---|---|
| GPT-6 | FSLR, CRM, CCC, CVX, IREN | -0.42% | 60% |
| Muse Spark 1.1 | CRM, FSLR, AMZN, MSFT, TSLA | +0.72% | 60% |
| Gemini 3 Pro | NVDA, MSFT, QQQ, AAPL, AMZN | +0.71% | 80% |
| Perplexity | CCI, MRNA, HUM, NVAX, FSLY | -0.84% | 40% |
| Grok 4.5 | XLE, XOM, CRM, DHT, JPM | +1.16% | 80% |
| Claude Sonnet 5.5 | XOM, JPM, NVDA, CVX, XLU | +0.28% | 60% |
Written up on ForecastNest Insights: Stock Selection: DeepSeek's picks for 2026-10-12.
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.